Genetic polymorphism in EGF Is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3367-3371

  Teixeira, Ana L ^a,d   Ribeiro, Ricardo ^a,d   Cardoso, Diana ^a   Pinto, Daniela ^a,b   Lobo, Francisco ^c   Fraga, Avelino ^e   Pina, Francisco ^f   Calais da Silva, Fernando ^g   Medeiros, Rui ^a,b,c,d  

^a Molecular Oncology Group CI   (Portugal)

^b Virology Department   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e Hospital Militar do Porto   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g Lisbon Regional Blood Centre   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; ANDROGEN; ANTIANDROGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN AGONIST; GUANINE NUCLEOTIDE;

AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; EGF GENE; GENE; GENETIC VARIABILITY; HORMONE RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; CASE CONTROL STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; PATHOLOGY; PROSTATE TUMOR; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANDROGEN ANTAGONISTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 50349084344     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5119     Document Type: Article

References (44)

1. Hsing Aw, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388-413.
2. Pronzato P, Rondini M. Hormonotherapy of advanced prostate cancer, Ann Oncol 2005;4:iv80-4.
3. Calabro F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol 2007; 51:17-26.
4. Harper ME. Goddard L, Glynne-Jones E, et al. Multi-pie responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. Prostate 2002;52:59-68.
5. Feldman BJ. Feldman D The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
6. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani E-N. Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 2003;5:99-109.
7. Craft N, ShostakY, Carey M, Sawyers CL A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
8. Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27 Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 1999:5:2171-7.
9. Vicentini C, Festuccia C, Gravina GL, Angelluci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 2003;129:165-75.
10. Di Lorenzo G.Tortora G, DArmiento F, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
11. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
12. Bhowmick D, Zhuang Z, Wait SD.Weil R. Afunctional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004;64:1220-3.
13. Costa B, Ferreira P, Costa P. et al. Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res 2007;13:2621-5.
14. Hamai Y Matsumura S, Matsusaki K, et al. A single nucleotide polymorphism 5'untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology 2004;72:133-8.
15. Okamoto I, Roka F, KröglerJ, et al.The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol 2006;126:2242-6.
16. Ribeiro R, Soares A, Pinto D. Catarino R, Lopes C, Medeiros R. EGF genetic polymorphism is associated with clinical features but not malignant phenotype in neurofibromatosis type 1 patients. J Neurooncol 2007;81:225-9.
17. Mullenbach R, Lagoda PJ, Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 1989;5:391.
18. Angelucci A, Schenone S, Gravina G, et al. Pyrazolo [3,4-rf] pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer 2006;42:2838-45.
19. El Sheikh SS. Domin J, Abel P, Stamp G, Lalani E-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004;6:846-53.
20. Harper ME, Glynne-Jones E, Goddard L, Mathews P, Nicholson Rl. Expression of androgen receptor and growth factors in premalignant lesions of the prostate. J Pathol 1998;186:169-77.
21. Sato B. Can an autocrine loop explain sex-hormone-dependent tumour growth? A brief overview. Oncology 1999;57:3-6.
22. Normanno N, Kim N, Wen D, et al. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat 1995;35:293-7.
23. Miguel P, Royuela M, Bethencourt R, Ruiz A, Fraile B, Paniagua R. Immunohistochemical comparative analysis of transforming growth factor α epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine1999;11:722-7.
24. Yotsumoto F, Yagi H, Suzuki SO. et al. Validation of HB-EGF and amphiregulin as target for human cancer therapy. Biochem Biophys Res Commun 2008:365: 555-61.
25. KarashimaT, Sweeney P, Slaton J, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody Imclone c225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002;8:1253-64.
26. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modelling of prostate cancer progression. Nat Genet 2007:39:41 -51.
27. Aaronson SA. Growth factors and cancer. Science 1991;254:1146-53.
28. Long R, Morrissey C, Fitzpatrick J. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci 2005; 108:1-11.
29. MercurioAM, Rabinovitz I, Shaw LM. The α6β4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001;13:541-5.
30. Shaw LM, Rabinovitz I, Wang HHJokerA, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the α6β4 integrin promotes carcinoma invasion. Cell 1997;91:949-60.
31. Tampellini M, Longo M, Cappia S, et al. Co-expression of EGF receptor, TGFα and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis. Virchows Arch 2007:450: 321-8.
32. Zolfaghari A, Djakiew D. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-prl) line by inhibition of epidermal growth factor receptor function. Prostate1996;28:232-8.
33. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997:70:722 6.
34. Angelucci A, Gravina GL, Rucci N, et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006:13:197-210.
35. Taille A, Vacherot F, Salomon L, et al. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis 2001:4: 204-12.
36. VisakorpiT Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet1995:9:401-6.
37. Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G, Baldi E. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 2007:38:51-66.
38. Festuccia G, Gravina GL, Angelucci A, et al. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 2005:115:630-40.
39. Belochitski 0, Ariad S, Shany S, Fridman V, Gavrilov V. Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1,25-dihydroxyvitamin D3. In Vivo 2007:21:371-6.
40. Mimeault M, Johansson SL, Vankatraman G, et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclop-amine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol CancerTher 2007;6:967-78.
41. Mimeault M, Venkatraman G, Johansson SL, et al. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 2007:120:160 - 9.
42. Busby JE, Kim SJ, Yazici S, et al. Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells. Prostate 2006;66:1788-98.
43. Salzberg M, Rochlitz C, Morant R, et al. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 2007;30:355-60.
44. Curigliano G, Pelosi G, De PasT et al. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. Prostate 2007;67:603-4.